GTCM
VNDA icon

Gyon Technologies Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Gyon Technologies Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-15,819
Closed -$248K – 577
2021
Q4 		$248K Buy
+15,819
New +$276K 0.05% 462

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Gyon Technologies Capital Management's VNDA Position: Q1 2022 in Review

Gyon Technologies Capital Management sold out of Vanda Pharmaceuticals (VNDA) in Q1 2022, closing a stake of 15,819 shares — an estimated $248K sold.

Gyon Technologies Capital Management first reported a position in VNDA in Q4 2021 and held it in 1 quarter. The position peaked at $248K in Q4 2021. 188 funds tracked by Wall St. Rank hold VNDA as of Q1 2022.

  • Gyon Technologies Capital Management reported no remaining Vanda Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Gyon Technologies Capital Management sold 15,819 Vanda Pharmaceuticals shares in Q1 2022, an estimated $248K.
  • Gyon Technologies Capital Management first reported a position in Vanda Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Gyon Technologies Capital Management's Vanda Pharmaceuticals position peaked at $248K in Q4 2021.
  • 188 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2022.

Based on Gyon Technologies Capital Management's 13F filing for Q1 2022, filed 12 May 2022.